David A. Siegel Cabaletta Bio, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 831,900 shares of CABA stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

831,900

Previous 281,200 195.84%

Holding current value

$1.83 Million

Previous $1.33 Million 37.91%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.87 - $4.91 $1.03 Million - $2.7 Million	550,700 Added 195.84%	831,900 $1.83 Million
Q3 2024 Nov 14, 2024	BUY	$3.94 - $8.24 $822,278 - $1.72 Million	208,700 Added 287.86%	281,200 $1.33 Million
Q2 2024 Aug 14, 2024	BUY	$7.22 - $18.82 $523,450 - $1.36 Million	72,500 New	72,500 $542,000
Q3 2022 Nov 14, 2022	SELL	$0.63 - $2.05 $82,467 - $268,345	-130,900 Reduced 70.64%	54,400 $35,000
Q2 2022 Aug 15, 2022	BUY	$0.99 - $2.11 $1,188 - $2,532	1,200 Added 0.65%	185,300 $196,000
Q1 2022 May 16, 2022	BUY	$1.68 - $3.92 $178,080 - $415,520	106,000 Added 135.72%	184,100 $374,000
Q4 2021 Feb 14, 2022	BUY	$3.36 - $14.64 $127,680 - $556,320	38,000 Added 94.76%	78,100 $296,000
Q3 2021 Nov 15, 2021	BUY	$7.0 - $12.5 $194,600 - $347,500	27,800 Added 226.02%	40,100 $488,000
Q2 2021 Aug 16, 2021	SELL	$7.2 - $11.73 $25,920 - $42,228	-3,600 Reduced 22.64%	12,300 $106,000
Q1 2021 May 17, 2021	BUY	$10.39 - $14.53 $11,429 - $15,983	1,100 Added 7.43%	15,900 $176,000
Q4 2020 Feb 16, 2021	SELL	$9.81 - $15.8 $17,658 - $28,440	-1,800 Reduced 10.84%	14,800 $185,000
Q3 2020 Nov 16, 2020	SELL	$9.71 - $14.41 $3,884 - $5,764	-400 Reduced 2.35%	16,600 $180,000
Q2 2020 Aug 14, 2020	BUY	$6.39 - $11.28 $108,630 - $191,760	17,000 New	17,000 $189,000

Others Institutions Holding CABA

# of Institutions

115

Shares Held

39.6M

Call Options Held

297K

Put Options Held

98.6K

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $63.8M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account